Mechanisms of osteoporosis therapy: A bone strength perspective

Clinical Cornerstone

Volumn 5, Issue SUPPL. 2, 2003, Pages

  Bouxsein, Mary L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE; PLACEBO; RISEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE MATRIX; BONE MINERAL; BONE MINERALIZATION; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CONTROLLED STUDY; DISEASE COURSE; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HUMAN; INHIBITION KINETICS; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; POROSITY; RISK ASSESSMENT; SWINE; TRABECULAR BONE; TREATMENT OUTCOME; BONE; PHYSIOLOGY; REVIEW; WEIGHT BEARING;

BONE AND BONES; BONE DENSITY; BONE REMODELING; CALCIFICATION, PHYSIOLOGIC; HUMANS; OSTEOPOROSIS; POROSITY; WEIGHT-BEARING;

EID: 0345688919     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(03)90043-3     Document Type: Article

References (25)

1. Rice JC, Cowin SC, Bowman JA. On the dependence of the elasticity and strength of cancellous bone on apparent density. J Biomechanics. 1988;21:155-168.
2. Carter DR, Hayes WC. The compressive behavior of bone as a two-phase porous structure. J Bone Jt Surg. 1977;59-A:954-962.
3. Mosekilde L. The effect of modelling and remodelling on human vertebral body architecture. Technol Health Care. 1998;6:287-297.
4. Bouxsein ML, Courtney AC, Hayes WC. Ultrasound and densitometry of the calcaneus correlate with the failure loads of cadaveric femurs. Calcif Tissue Int. 1995;56:99-103.
5. Moro M, Hecker AT, Bouxsein ML, Myers ER. Failure load of thoracic vertebrae correlates with lumbar bone mineral density measured by DXA. Calcif Tissue Int. 1995;56:206-209.
6. Cheng XG, Nicholson PH, Boonen S, et al. Prediction of vertebral strength in vitro by spinal bone densitometry and calcaneal ultrasound. J Bone Miner Res. 1997;12:1721-1728.
7. Cheng XG, Lowet G, Boonen S, et al. Assessment of the strength of proximal femur in vitro: Relationship to femoral bone mineral density and femoral geometry. Bone. 1997;20:213-218.
8. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996; 312:1254-1259.
9. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: Scientific review. JAMA. 2002; 288:1889-1897.
10. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359:2018-2026.
11. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002;17:1-10.
12. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-289.
13. Meunier PJ, Boivin G. Bone mineral density reflects bone mass but also the degree of mineralization of bone: Therapeutic implications. Bone. 1997;21:373-377.
14. Zanchetta J, Bogado C, Ferretti J, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003;18:539-543.
15. Silva MJ, Gibson LJ. Modeling the mechanical behavior of vertebral trabecular bone: Effects of age-related changes in microstructure. Bone. 1997;21:191-199.
16. Borah B, Dufresne T, Chmielewski P, et al. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized mini-pigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res. 2002;17:1139-1147.
17. Dufresne T, Chmielewski P, Borah B, Prenger M. One year treatment with risedronate preserves trabecular architecture. J Bone Miner Res. 2002; 17(Suppl 1):S368.
18. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res. 2001;16:1846-1853.
19. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344: 1434-1441.
20. Bell KL, Loveridge N, Power J, et al. Regional differences in cortical porosity in the fractured femoral neck. Bone. 1999;24:57-64.
21. Bell KL, Loveridge N, Jordan GR, et al. A novel mechanism for induction of increased cortical porosity in cases of intracapsular hip fracture. Bone. 2000;27:297-304.
22. Roschger P, Rinnerthaler S, Yates J, et al. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone. 2001;29:185-191.
23. Currey JD. The effect of porosity and mineral content on the Young's modulus of elasticity of compact bone. J Biomechanics. 1988;21:131-139.
24. Hernandez CJ, Beaupre GS, Keller TS, Carter DR. The influence of bone volume fraction and ash fraction on bone strength and modulus. Bone. 1988; 29:74-78.
25. Boivin GY, Chavassieux PM, Santora AC, et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000;27:687-694.